Review
Published · Updated · 1 min read
Fluorouracil and capecitabine: full DPYD sequencing to identify toxicity risk
What it means for practice
Full DPYD sequencing may be considered to identify rare variants associated with DPD deficiency in patients receiving fluoropyrimidines. Cost-effectiveness depends on the healthcare system’s willingness to pay per additional QALY.
Summary
The article reviews full DPYD gene sequencing to identify dihydropyrimidine dehydrogenase (DPD) deficiency in patients receiving fluoropyrimidines, including fluorouracil and capecitabine. The aim of this testing is to identify individuals in whom enzyme deficiency is associated with a risk of severe treatment-related toxicity.
Full gene sequencing can identify rare and novel DPYD variants. According to the description provided, this could potentially reduce the risk of severe toxic reactions. The authors also emphasize the importance of comprehensive testing for addressing health inequities and improving patient safety by identifying individuals at risk of adverse events due to DPD deficiency.
The cost-effectiveness of full gene sequencing depends on the healthcare system’s willingness to pay per additional quality-adjusted life year (QALY). The abstract provides no specific cost threshold, quantitative estimate of toxicity reduction, or description of study limitations. It therefore does not establish the magnitude of clinical benefit or the specific conditions under which testing is cost-effective.
Source
-
Full Gene Sequencing for DPD Deficiency Testing.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
